Navigation Links
Bacterin International Holdings, Inc. to Present at the 6th Annual Fall Growth Stock Conference Hosted by Security Research Associates, Inc.
Date:10/8/2010

BELGRADE, Mont., Oct. 8 /PRNewswire/ -- Bacterin International Holdings, Inc. (OTC Bulletin Board: BIHI) ("Bacterin"), today announced Guy Cook, President & CEO of Bacterin will be presenting at the 6th Annual Fall Growth Stock Conference hosted by Security Research Associates, Inc. ("SRA").  The conference will be held on Tuesday, October 26th at the Westin St. Francis in San Francisco.  Bacterin is scheduled to present at 1:00 p.m. (PT).  The presentation will be broadcast live over the Internet and can be accessed at http://www.wsw.com/webcast/sra11/bihi.ob/ or through the Company's website at www.bacterin.com.

Conference attendees will include a select group of institutional portfolio managers and analysts and will feature CEOs and CFOs from some of the fastest growing companies in the technology sector.  SRA has arranged for webcasting of company presentations during this event, which can be accessed on the lobby page for the webcast of presenting companies at http://www.wsw.com/webcast/sra11/.

Bacterin, founded in 1998 as a spin out from the National Science Foundation's Center for Biofilm Engineering, is a developer of unique, anti-infective coatings for medical applications and a producer of revolutionary scaffolds for tissue regeneration.  

About Bacterin International Holdings, Inc.

BACTERIN INTERNATIONAL HOLDINGS, INC. ("Bacterin") develops, manufactures and markets biologics products to domestic and international markets.  Bacterin's proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold and promote bone and other tissue growth.  These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain by facet joint stabilization, promotion of bone fusion in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral bone defect repair in articulating joint surgeries.

Bacterin's Medical Device division develops anti-microbial coatings based upon proprietary coating technologies.  Bacterin develops, employs, and licenses bioactive coatings for various medical device applications.  Bacterin's strategic coating initiatives include antimicrobial coatings designed to inhibit biofilm formation and microbial contamination on medical devices drug delivery, local (as opposed to systemic) pain management, and anti-thrombotic factors for medical device applications.  

Headquartered in Belgrade, Montana, Bacterin operates a 32,000 square foot, state-of-the-art, fully compliant and FDA registered facility, equipped with four "Class 100" clean rooms.  For further information please visit www.bacterin.com.

About Security Research Associates, Inc.

Security Research Associates, Inc. (SRA) was founded in San Francisco in 1980 and, today, offers investment banking and M&A services as well as institutional brokerage services.  A boutique firm by design, SRA works with a select group of portfolio managers from around the country and focuses on technology and life science companies in the micro and small cap arenas.  For more information about SRA see our web site at www.sracap.com or call us at 415-925-0346.

Certain statements in this news release may constitute "forward-looking" statements within the meaning of section 21E of the Securities and Exchange Act of 1934.  The Company believes that its expectations, as expressed in these statements are based on reasonable assumptions regarding the risks and uncertainties inherent in achieving those expectations.  These statements are not, however, guarantees of future performance and actual results may differ materially.  Risk factors are listed in the most recent 8-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission.  


'/>"/>
SOURCE Bacterin International Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bacterin International Holdings, Inc. Completes Merger and $7.5 Million Raise
2. Bacterin International Secures Three-Year Agreement to Distribute Biologic Products to Broadlanes Network of Over 6,000 Medical Facilities
3. Bacterin International Introduces OsteoSelect(R) DBM Putty
4. Bacterin International Completes $3 Million Private Placement
5. PRA International to Exhibit at European Oncology Congress
6. International Menopause Society Calls Upon Medical Community to Improve the Vaginal Health of Postmenopausal Women
7. International Medical News Group Relaunches Internal Medicine News Digital Network and Hospitalist News Digital Network
8. Stemedica International Announces Joint Venture with AnC Bio Group
9. Archimedes Pharma Announces Publication of a Pivotal Clinical Study of Fentanyl Pectin Nasal Spray (FPNS) in Pain, the Peer-Reviewed Journal from the International Association for the Study of Pain
10. Dendreon Announces Presentation of PROVENGE Data at the 25th International Society for Biological Therapy of Cancer Annual Meeting
11. Max Neeman International Initiates Large Phase IV Trial on Type II Diabetes with 25,000 Subjects Across 1,200 Sites
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... -- Wound care devices and products are used to ... industry mainly consists of establishments engaged in manufacturing wound ... caused by mechanical, chemical, thermal, and radiogenic trauma; and ... skin related diseases, immunological diseases, and other chronic diseases. ... largest region in the wound care devices market in ...
(Date:3/29/2017)... , March 29, 2017 Global intravenous (IV) iron ... billion by 2021, growing at a CAGR of 5%. ... by a doctor to treat anemia or other iron deficiencies. ... in the body. However, in some cases, oral administrations are ... and intravenous (IV) iron therapy comes into the picture. ...
(Date:3/29/2017)... N.J. , March 29, 2017  Novartis ... Administration (FDA) has accepted the company,s Biologics License ... CTL019 (tisagenlecleucel-T), an investigational chimeric antigen receptor T ... pediatric and young adult patients with B-cell acute ... submission by Novartis for a CAR-T. The priority ...
Breaking Medicine Technology:
(Date:3/30/2017)... DC (PRWEB) , ... March 30, 2017 , ... ... and organizations submitted a letter to President Trump expressing their support for an ... medical doctors, two Ph.D. scientists and one medical journalist, will hold a press ...
(Date:3/29/2017)... ... March 29, 2017 , ... In the United States alone, up ... year develop other types of metastatic brain tumors(3). Though most meningiomas are benign, metastatic ... focus on finding more effective treatment options, the San Diego Gamma Knife Center ...
(Date:3/29/2017)... ... 2017 , ... Grass pollen is the main cause of hay fever in the United States, ... grass pollen runs from May to July each year; with the worst time for sufferers ... allergen barrier balms ( http://www.haymax.us ) provide an effective defense against grass pollen; they are ...
(Date:3/29/2017)... FL (PRWEB) , ... March 30, 2017 , ... Sublime ... the "Spice of Life" or "Wonder Spice", it has been used for thousands of ... in the East," says Heshelow, author of " Turmeric: How to Use it For ...
(Date:3/29/2017)... ... March 29, 2017 , ... AngioGenesis Labs ... store in Mississippi. AngioGenesis Labs, makers of HeartBoost, BrainBest and BeautyBest, achieved these ... Ingredients in HeartBoost, an over the counter heart healthy drink, can reduce Arterial ...
Breaking Medicine News(10 mins):